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ABSTRACT: 
Cystic fibrosis (CF) mutations have complex effects on the cystic fibrosis 
transmembrane conductance regulator (CFTR) protein.  They disrupt its 
processing to and stability at the plasma membrane and function as an ATP-
gated Cl- channel.  Here, we review therapeutic strategies to overcome 
defective CFTR processing and stability.  Because CF mutations have 
multiple impacts on the assembly of CFTR protein, combination therapy with 
several pharmacological chaperones is likely to be required to rescue 
mutant CFTR expression at the plasma membrane.  Alternatively, 
proteostasis regulators, proteins which regulate the synthesis, intracellular 
transport and membrane stability of CFTR might be targeted to enhance the 
plasma membrane expression of mutant CFTR.  Finally, we consider an 
innovative approach to bypass CFTR dysfunction in CF, the delivery of 
artificial anion transporters to CF epithelia to shuttle Cl- across the apical 
membrane.  The identification of therapies or combinations of therapies, 
which rescue all CF mutations, is now a priority. 
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HIGHLIGHTS: 
 Many CF mutations disrupt the processing and/or function of the CFTR 
Cl- channel 
 Combinations of CFTR correctors are needed to optimally rescue CF 
processing mutants 
 Proteostasis regulators have been identified that rescue F508del-
CFTR 
 Artificial anion transporters are an alternative strategy to bypass 
CFTR loss in CF 
 
 
Cystic Fibrosis (CF) is caused by loss-of-function mutations in the gene 
encoding the cystic fibrosis transmembrane conductance regulator (CFTR) 
[1], an ATP-binding cassette (ABC) transporter expressed at the apical 
membrane of many epithelia, which functions as an ATP-gated anion 
channel [2].  Approximately 2,000 mutations have been identified in the 
CFTR gene (http://www.genet.sickkids.on.ca/app), but most are very rare 
and not all lead to a defective protein or manifest as a clinical phenotype 
[3]. 
 
The most common CF mutation is the deletion of phenylalanine 508 
(F508del), which reduces the intrinsic stability of the first nucleotide-
binding domain (NBD1) and perturbs interactions between NBD1 and NBD2 
as well as those between NBD1 and the membrane-spanning domains 
(MSDs) [4].  Such abnormalities lead to misfolding of F508del-CFTR, 
ubiquitination in the endoplasmic reticulum (ER) and premature 
degradation by the proteasome [5,6].  Any F508del-CFTR that reaches the 
plasma membrane exhibits reduced stability [7] and defective channel 
gating [8]. 
 
To address the most prevalent defects leading to CF, two biomolecular 
activities are required, namely CFTR correctors to increase the amount of 
properly folded F508del-CFTR protein at the plasma membrane, and CFTR 
potentiators to allow effective gating (i.e. function) of F508del-CFTR [4,9].  
When combined, these biomolecular activities restore transepithelial Cl- 
transport to CF airway epithelia expressing F508del-CFTR, improving 
hydration and restoring mucociliary clearance [10].  At present, two orally-
bioavailable small molecules with biomolecular activities targeting mutant 
CFTR are commercially available for CF patients: the CFTR corrector 
Lumacaftor (VX-809) and the CFTR potentiator Ivacaftor (VX-770) [10,11].  
Ivacaftor is approved for use with 33 CF mutations causing gating defects 
(https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm5
59212.htm).  By contrast, Lumacaftor-Ivacaftor combination therapy 
(Orkambi) is currently available only to CF patients homozygous for 
F508del-CFTR [12]. 
 
CFTR potentiators bind directly to mutant CFTR to improve channel gating 
after CFTR phosphorylation by PKA [9].  By contrast, some CFTR correctors 
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act as pharmacological chaperones while others are proteostasis regulators 
[13,14].  Pharmacological chaperones act directly on mutant CFTR, 
stabilizing specific CFTR domains and/or improving the interactions of 
different CFTR domains [15].  Proteostasis regulators modulate the 
proteostasis environment, leading to beneficial effects on CFTR processing 
and plasma membrane stability [14].  Regardless of their mechanism of 
action, the use of a single CFTR corrector is insufficient to achieve 
therapeutically-relevant rescue of F508del-CFTR [15,16].  The data suggest 
that drug therapy for CF will require combinations of CFTR correctors 
exploiting different mechanisms of action with additive/synergistic efficacies 
[17,18]. 
 
Other therapeutic strategies for CF are termed mutation-independent 
because they are applicable to all individuals with CF irrespective of the CF 
mutations that they carry.  One mutation-independent therapeutic strategy 
is to bypass CFTR dysfunction by activating other apical membrane Cl- 
channels in CF epithelia [19].  An innovative approach to bypass CFTR 
dysfunction is to deliver to the apical membrane of CF epithelia artificial 
anion channels or transporters [20].  Here, we review selectively recent 
progress in the development of pharmacological chaperones, proteostasis 
regulators and artificial anion transporters. 
 
 
PHARMACOLOGICAL CHAPERONES TO RESTORE CFTR FUNCTION 
The biggest recent breakthrough in CF therapeutics has been the 
development of CFTR potentiators and CFTR correctors that target directly 
the basic defect in CF, mutant CFTR.  Due to the significant progress made 
towards understanding the relationship between CF genotype and 
subsequent causes of phenotype variation in CF, different CFTR variants can 
be classified as “theratypes”, depending upon their response to these CFTR 
modulators [3].  Indeed, these small molecule modulators most likely serve 
as personalized medicines for CF, which work by disease-modifying 
mechanisms [18]. 
 
Early studies of CFTR correctors identified that there was a “therapeutic 
ceiling” with maximal correction about 20% wild-type CFTR function [21,22].  
An explanation for the limited effectiveness of first generation CFTR 
correctors is the wide-ranging impact of F508del-CFTR on CFTR assembly, 
perturbing domain-domain interactions [4].  Studies of revertant mutations 
demonstrated that the therapeutic ceiling could be exceeded by 
simultaneously targeting multiple defects in CFTR folding and assembly 
[15,16].  These data provided the rationale for combination therapy with 
CFTR correctors, pharmacological chaperones that bind directly to mutant 
CFTR to exert their effects [23,24].  Figure 1 provides examples of different 
CFTR correctors (C1- and C2-type) in development by pharmaceutical 
companies.  C1-type correctors target early folding of mutant CFTR while 
C2-type correctors have novel mechanisms of action that complement C1-
type correctors.  When used together, either by themselves or with CFTR 
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amplifiers (small molecules which target an early step in the biosynthesis 
of CFTR to increase the amount of CFTR protein [25]), C1- and C2-type 
correctors are expected to deliver sufficient F508del-CFTR to the plasma 
membrane to achieve far greater clinical benefit than that observed with 
Lumacaftor alone [12].  When used together with a CFTR potentiator (Figure 
1), triple combination therapy is expected to be transformative for 
individuals with the F508del-CFTR mutation. 
 
 
 
 
Figure 1: Triple combination therapy for CF.  The molecular mechanisms of 
CFTR dysfunction in CF are shown together with small molecule CFTR modulators 
that act as potentiators (P), C1-type correctors and C2-type correctors.  Marketed 
drugs and drug candidates in development for the three classes of CFTR 
modulators are listed. Pharmaceutical companies involved with the development 
of these drugs are AbbVie/Galapagos, Concert Pharmaceuticals, Flatley Discovery Lab, 
Novartis, Proteostasis Therapeutics and Vertex Pharmaceuticals. 
 
 
One of the major challenges being faced by future CFTR correctors is the 
need for broader beneficial efficacy for all CF patients (i.e. targeting all CF 
mutations disrupting CFTR processing and membrane stability).  Just as for 
F508del-CFTR, triple combination therapy consisting of two corrector 
molecules and a potentiator will likely have greatest benefit for rare CF 
mutations (Figure 1).  Of all the different combinations that are currently in 
development, ones that achieve safe and efficacious “best-in-class” profiles, 
benefiting all CF patients will prevail in the end. 
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PROTEOSTASIS REGULATORS 
Several proteins have already been identified that could represent useful 
drug targets for a CF therapy based on proteostasis modulation [13,14,26]. 
Molecular chaperones such as Hsp90 and its co-chaperone partner AHA1 
are thought to play a key role in facilitating CFTR folding [27], as well as 
targeting folding-deficient F508del-CFTR for degradation (Figure 2).  Thus, 
pharmacological inhibition of the Hsp90-AHA1 chaperone complex appears 
beneficial to prevent proteolysis of mutant CFTR and rescue its residual 
activity.  Consistent with this idea, Ihrig and Obermann [28] identified two 
molecules that restored Cl- channel activity to F508del-CFTR by inhibiting 
the Hsp90-AHA1 chaperone complex.  Interestingly, the Hsp90-AHA1 
inhibitors were most effective in combination with the CFTR corrector 
Lumacaftor and might therefore serve as leads that can be further 
developed into a combination therapy to treat CF patients [28]. 
 
 
 
 
Figure 2: Proteostasis regulators as targets for CF drug development.  The 
schematic shows the synthesis of CFTR in the ER and its transport to and recycling 
from the plasma membrane.  Selected proteostasis regulators that represent 
targets for CF drug development are indicated and discussed in the text.  
Abbreviations: AHA1: Activator of Hsp90 ATPase Activity 1; AP2: Assembly 
Polypeptide-2; CHIP: Hsp70-interacting protein; COMMD1: Copper Metabolism 
Domain Containing 1; Dab2: Disabled-2; DERL1: Derlin-1; p97/VCP: 97 kDa 
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Valosin Containing Protein; RNF5: Ring Finger Protein 5; Ubc6: ubiquitin-
conjugating enzyme E2 6. 
 
 
Other possible drug targets are proteins in the ER quality control pathway 
known as ER-associated degradation (ERAD), including chaperones, 
components of the retro-translocon (DERL1, p97/VCP) [29], proteins 
responsible for extracting ubiquitinylated substrates from the ER membrane 
(gp78) [30] and cytosolic and membrane-associated E3 ubiquitin ligases 
(e.g. RNF5).  RNF5 (also known as RMA1) is a component of an ER-
associated E3 ubiquitin ligase complex that contains Ubc6e and the 
transmembrane quality-control factor DERL1 [29] (Figure 2).  The RNF5 E3 
complex appears to sense the assembly status of N-terminal regions of 
CFTR at a folding step that occurs prior to NBD2 synthesis and is therefore 
defective in F508del-CFTR [31]. 
 
Tomati et al. (2015) demonstrated that RNF5 is a potential CF drug target 
using cultured cells and transgenic mice.  In vitro studies showed that RNF5 
knockdown strongly enhanced F508del-CFTR activity and increased the 
traffic of immature, partially glycosylated CFTR to the plasma membrane 
by an unconventional secretory pathway dependent on GRASP protein 
activity [32].  Rescue of mutant CFTR by RNF5 knockdown also displayed 
additive/synergistic effects with the CFTR corrector Lumacaftor [32], 
suggesting that each manipulation affects distinct pools of mutant CFTR. 
 
To investigate whether RNF5 suppression might rescue F508del-CFTR in 
vivo, transgenic F508del-CFTR mice were crossed with RNF5 knockout mice 
[32].  Although homozygous F508del-CFTR mice lack the respiratory 
symptoms characteristic of CF in humans, they display CF gastrointestinal 
pathology [33].  Of note, in vivo RNF5 suppression ameliorated the 
gastrointestinal pathology observed in homozygous F508del-CFTR mice 
[32].  The number of animals with severely reduced body weight was 
significantly reduced, as well as fecal loss of biliary acids [32].  In parallel, 
short-circuit current measurements of duodenal Cl- secretion in RNF5 
knockout, homozygous F508del-CFTR mice showed a 5-fold increase in 
CFTR activity [32].  Together the in vitro and in vivo data demonstrate 
clearly the benefits of RNF5 knockdown [32].  Thus, RNF5-targeting 
inhibitors have the potential to ameliorate disease in CF patients bearing 
the F508del mutation. 
 
Other proteins that constitute putative drug targets for CF are COMMD1 and 
CHIP (Figure 2).  Indeed, COMMD1-mediated ubiquitylation regulates 
protein trafficking to the plasma membrane, and it acts either by enhancing 
the cell surface expression of CFTR or the internalization of the epithelial 
Na+ channel (ENaC) [26,34].  The ubiquitin E3 ligase CHIP participates in 
two different steps of CFTR biogenesis and processing [26].  In particular, 
CHIP, in complex with the cytosolic Hsc/Hsp70, cooperates with the ER 
membrane-associated ubiquitin ligases complex (containing RNF5, Ubc6e, 
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and DERL1) to triage wild-type and F508del-CFTR.  Interestingly, CHIP also 
plays a role at the plasma membrane, where it is responsible for 
ubiquitylation of the mutant channel, acting in concert with Dab2 to target 
rescued F508del-CFTR to the lysosome [26]. 
 
Luciani et al. [35] demonstrated that the accumulation of misfolded 
F508del-CFTR in protein aggregates is a consequence of defective 
autophagy caused by transglutaminase-mediated depletion of beclin-1.  
Building on these data, De Stefano et al. [36] showed that restoration of 
beclin-1-dependent autophagy using the FDA-approved drug cysteamine 
reduces the mortality of CF mice bearing the F508del mutation and 
improves F508del-CFTR protein expression in the nasal epithelium of CF 
patients homozygous for F508del-CFTR.  These data encourage further 
clinical testing of cysteamine in CF patients. 
 
Once delivered to the plasma membrane, wild-type CFTR resides for 
prolonged periods (half-life, ~24 h), whereas F508del-CFTR is highly 
unstable (half-life, ~4 h) [7].  The reduced stability of F508del-CFTR at the 
plasma membrane reflects both the intrinsic instability of the mutant 
protein itself [37,38] and accelerated endocytosis of the mutant protein 
[39,40].  Therefore, addressing the plasma membrane instability of rescued 
F508del-CFTR might represent a therapeutic approach complementary to 
biosynthetic rescue of the mutant protein.  Targets to improve CFTR 
stabilization at the apical plasma membrane include proteins involved in 
either endocytic retrieval or lysosomal degradation of the protein.  The 
Dab2-AP2 complex facilitates endocytosis of CFTR by recruiting it with 
adaptor proteins (Figure 2).  Consistent with this idea, RNAi-induced 
depletion of Dab2 inhibited F508del-CFTR endocytosis, increasing the half-
life of the mutant CFTR by 91% [41].  Moreover, a peptide that binds the 
Dab2 DH peptide-binding pocket regulates CFTR abundance at the plasma 
membrane [42].  Therefore, peptides or drug-like small molecules, which 
inhibit the Dab2 DH peptide-binding pocket, might provide pharmacological 
approaches to stabilise F508del-CFTR at the plasma membrane.  
 
 
ARTIFICIAL ANION TRANSPORTERS 
Some CF mutations currently appear less amendable to rescue with CFTR 
modulators.  For these CF mutations, mutation-independent therapies are 
the therapeutic strategy of choice.  One approach to mutation-independent 
therapy aims to restore transepithelial Cl- secretion to CF epithelia by 
utilising other apical membrane pathways for anion movement.  Most work 
in this area has focused on endogenously expressed apical membrane Cl- 
channels, particularly the Ca2+-activated Cl- channel TMEM16A [19].  
However, the Cl- channel SLC26A9 has emerged as an attractive target 
because it mediates sustained Cl- secretion, whereas that of TMEM16A is 
transient [19]. 
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An innovative alternative approach to bypass CFTR dysfunction is to deliver 
to the apical membrane of CF epithelia an exogenous pathway for 
transmembrane anion movement.  The absence of suitable natural products 
has stimulated efforts to develop artificial anion channels and transporters.  
Proof of principle for this approach was achieved using peptides based on 
the Cl--selective pore of the glycine receptor [43]. 
 
Other studies have sought to develop artificial anion transporters 
(anionophores) that shuttle Cl- across a lipid bilayer by a mechanism similar 
to that of the K+ ionophore valinomycin, which acts as a mobile carrier 
[20,44] (Figure 3).  Using the steroid cholic acid as a scaffold, the Anthony 
P. Davis group generated a family of anionophores termed cholapods [44].  
These anionophores possess pre-organised anion-binding sites capable of 
very high affinities linked to lipophilic scaffolds, which promote solubility in 
lipid bilayers [45,46].  Using synthetic phospholipid vesicles, cholapods 
were shown to transport Cl- across lipid bilayers with high affinity (i.e. 
cholapod:lipid ratios of 1:250,000) by an anion exchange mechanism and 
with renal epithelia, they were demonstrated to generate Cl--selective 
currents distinct from those of CFTR [45].  Several lines of evidence argued 
that cholapods function as mobile carriers rather than self-assembled 
channels: cholapod-mediated anion transport was dependent on 
transporter concentration, membrane fluidity and membrane thickness 
[45,46]. 
 
Using the common design motif of axially-directed hydrogen-bond donors 
in 1,5-relationships, the Anthony P. Davis group have developed other 
anionophores, including decalins [47,48] and cyclohexanes [49]. To 
evaluate the biological activity of anionophores, a fluorescence-based 
protocol was developed using halide-sensitive yellow fluorescent protein 
(YFP)-H148Q/I152L [50,51], which has been used with great success to 
identify small molecule CFTR modulators.  Among the anionophores tested 
by Li et al. [50], a bis-(p-nitrophenyl)ureidodecalin was shown to be highly 
active using both the fluorescence-based protocol and the Ussing chamber 
technique (Figure 3). This anionophore was deliverable to cell membranes, 
potent at micromolar concentrations and its activity was long-lasting [50].  
Moreover, when tested on three different epithelial cell lines, the bis-(p-
nitrophenyl)ureidodecalin was without cytotoxic effects [50].  One possible 
explanation for the notable biological activity of the bis-(p-
nitrophenyl)ureidodecalin is that among all the anionophores tested by Li 
et al. [50], it most closely satisfied Lipinski’s rule of five for drug-like 
molecules [52]. 
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Figure 3: Transmembrane anion transport by anionophores.  A, the crystal 
structure of the anionophore bis-(p-nitrophenyl)ureidodecalin in the absence and 
presence of Cl-.  Dashed lines denote hydrogen bonds that bind the Cl- ion.  B, 
schematic of transmembrane anion transport by anionophores.  The bis-(p-
nitrophenyl)ureidodecalin anionophore is shown transporting I- across the 
membrane in exchange for Cl-, which occurs when anionophores mediate the 
uptake of I- by YFP-expressing Fischer rat thyroid cells leading to fluorescence 
quenching. 
 
 
The identification of an anionophore with promising biological activity 
argues that anionophores merit further investigation as a mutation-
independent therapy for CF. However, additional understanding of anion 
transport by anionophores is required, including structure-activity 
relationships, mechanism of action and cell biology.  Like valinomycin, 
which shields transported K+ within a lipophilic shell, anionophores with 
encapsulated Cl--binding sites achieve greater Cl--selectivity [53].  Thus, 
optimisation of the chemical structure of anionophores will likely lead to 
anionophores most suitable for CFTR bypass therapy. 
 
 
CONCLUSIONS 
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The widespread impact of CF mutations on CFTR processing argues that 
efficacious small molecule CFTR correctors are essential to develop disease-
modifying therapies for CF patients.  The data suggest that combinations of 
pharmacological chaperones that act directly on mutant CFTR will be 
required to achieve optimal rescue of the plasma membrane expression and 
stability of CF mutants [15,16].  Of note, the first of these CFTR corrector 
combination therapies recently gave positive results in phase 1 and phase 
2 clinical trials 
(http://investors.vrtx.com/releasedetail.cfm?ReleaseID=1033559).  While 
it is not known whether combination therapy begun early and used 
continuously will prevent disease symptoms developing over time, the data 
emerging from clinical trials are very encouraging.  Mutant CFTR rescue 
using CFTR correctors might be complemented with proteostasis regulators, 
which target molecular steps in CFTR processing, delivery to and stability 
at the plasma membrane.  The use of these agents might remove 
bottlenecks that obstruct the rescue of mutant CFTR.  However, 
proteostasis regulators might have untoward effects because they target 
key steps in the biosynthesis, traffic and stability of other proteins besides 
CFTR.  Future studies should address this possibility.  Mutation-independent 
therapies will likely be required for individuals with certain rare CF 
mutations resistant to rescue with small molecule CFTR modulators and 
proteostasis regulators.  Among the mutation-independent therapeutic 
strategies under consideration, anionophores might bypass CFTR 
dysfunction by shuttling Cl- across the apical membrane of CF airway 
epithelia.  Lessons from clinical trials of gene therapy [54] will need to be 
followed to optimise the delivery of anionophores to CF airway epithelia, 
while their activity might be controlled by modulation of basolateral 
membrane K+ channels [55].  Beyond the respiratory airways, innovative 
drug delivery strategies will be required to specifically target anionophores 
to other epithelial tissues affected by CF without causing untoward effects.  
Thus, the challenge now is to translate laboratory discoveries into disease-
modifying therapies for all individuals living with CF. 
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